Cordant Inc’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cordant Inc’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5	Closed	-$3K	–	202
2022 Q1	$3K	Buy	+5	New	+$3.01K	﹤0.01%	436

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cordant Inc's BIO Position: Q2 2022 in Review

Cordant Inc sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 5 shares — an estimated $3K sold.

Cordant Inc first reported a position in BIO in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

Cordant Inc reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
Cordant Inc sold 5 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $3K.
Cordant Inc first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 1 quarter.
Cordant Inc's Bio-Rad Laboratories Class A position peaked at $3K in Q1 2022.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Cordant Inc's 13F filing for Q2 2022, filed 17 Aug 2022.